US Digital Diabetes Management Market

The US digital diabetes management market is projected to reach USD 22.67 billion by 2031 from USD 12.94 billion in 2026, at a CAGR of 11.9% during the forecast period.

The case for diabetes and prediabetes in the US is on a steady incline due to several factors, including an aging population, obesity, sedentary lifestyle, and poor diet. Millions of patients require lifelong glucose monitoring, medication adherence, and lifestyle management, thus creating a strong demand for scalable digital solutions. Digital diabetes management platforms allow continuous monitoring, early detection of glycemic fluctuations, and long-term disease tracking. Digital tools help alleviate some of the clinical burden while improving outcomes, as healthcare systems face increasing patient volumes. This makes them an amenable solution for managing the growing diabetes population across the US.

In this report, the US digital diabetes market has been segmented based on product & service, device type, and end user.

To know about the assumptions considered for the study download the pdf brochure

Prominent players in this market include Medtronic (Ireland), B. Braun Melsungen AG (Germany), Dexcom, Inc. (US), Abbott Laboratories (US), F. Hoffmann-La Roche (Switzerland), Insulet Corporation (US), ARKRAY (Japan), ACON Laboratories, Inc. (US), Care Innovations, LLC (US), Health2Sync (Taiwan), Tandem Diabetes Care (US), Dottli (Finland), Ypsomed Holding AG (Switzerland), Emperra GmbH E-Health Technologies (Germany), Azumio (US), Ascensia Diabetes Care Holdings AG (Switzerland), LifeScan, Inc. (US), Tidepool (US), AgaMatrix (US), Glooko, Inc. (US), DarioHealth Corporation (Israel), Pendiq GmbH (Germany), One Drop (US), Decide Clinical Software GmbH (Austria), and BeatO (India).

Dexcom, Inc. (us)

Dexcom is in the top tier of the US digital diabetes management market. Its flagship Dexcom products are considered to be sweeping the field for continuous glucose monitoring systems. Its product lineup includes CGM systems such as the Dexcom G7 and iCGM System, the Dexcom G6 Continuous Glucose Monitoring (CGM) System, the Dexcom G5 Mobile CGM System, and the Dexcom One. The company operates 242 manufacturing and distribution facilities globally. Dexcom's strategy for increasing its share of digital diabetes management is through alliances, contracts, and acquisitions. In recent years, Dexcom has been forming partnerships to combine its CGM system with various insulin pumps. With a growing emphasis on expanding its global footprint, the company provides itself with significantly richer resources for the production and service of its customer base.

Medtronic (Ireland)

Medtronic has a broad product portfolio, which includes insulin pumps, smart glucose meters, CGM systems, mobile applications, data management software, and services. It has a presence in North America, Latin America, the US, Africa, the Middle East, and the Asia Pacific. The MiniMed 780 Systems, MiniMed 670 Systems, Guardian Connect CGM Systems, CareLinkdiabetes Personal Software, and StartRight Programs are part of Medtronic's entire digital portfolio for diabetes management. The organization emphasizes new product launches, innovation, and creating alliances and partnerships with other market players to maintain its primary position.

Abott (us)

The company provides CGM systems, smart insulin pens, smart insulin pumps, smart insulin patches, and data management software. It also offers connected glucose meters. Under the leading brand of Freestyle Libre, Abbott offers a comprehensive range of digital CGM devices for managing diabetes, along with software platforms that have gained much popularity among end users in countries across the globe. Abbott Laboratories also extends its operations to the Middle East, Africa, Asia, and North America. To stay at the top of their game, the company mainly concentrates on product launches, alliances, and collaborations. In October 2022, the company released a new CGM system called FreeStyle Libre 3-beta, which has significantly increased revenue.

Market Ranking

The US digital diabetes management market is highly consolidated, with prominent players accounting for over 70% of the total market share in 2025. Some of the players dominating the market include Medtronic (Ireland), Dexcom, Inc. (US), Abbott Laboratories (US), F. Hoffmann-La Roche (Switzerland), and Insulet Corporation (US).

The US digital diabetes management market is driven by the strong presence of multinational medical device companies and mature digital health players, supported by emerging domestic digital therapeutics and software providers. Companies are focusing on cost-effective connected glucose monitoring systems, mobile health applications, and cloud-based platforms to support value-based care models. Rising diabetes prevalence, improved reimbursement for CGM and remote patient monitoring, and sustained adoption of telehealth are encouraging strategic partnerships with providers, payers, and integrated health systems across the US.

Related Reports:

US Digital Diabetes Management Market By Product (Device (CGM, Smart Glucometer, Insulin Patch Pump), Diabetes Apps, Service, Software & Platforms), Device Type (Handheld & Wearables), End User (Self/Home Healthcare) - Global Forecast to 2031

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com